Neurocrine Biosciences stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 67 to 71.
This unique rating identifies market leadership by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
History shows that the best stocks tend to have an RS Rating north of 80 in the early stages of their moves. See if Neurocrine Biosciences stock can continue to show renewed price strength and clear that threshold.
When To Sell Stocks To Lock In Profits And Minimize Losses
Is Neurocrine Biosciences Stock A Buy?
Neurocrine Biosciences stock is building a cup without handle with a 157.98 entry. See if the biotech stock can clear the breakout price in volume at least 40% above average.
The biotech company showed 18% EPS growth in its most recent report. Sales rose 25%.
Neurocrine Biosciences stock holds the No. 3 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals is the top-ranked stock within the group.
